| Brand
Name Manufacturers |
Estrovis
by Parke-Davis |
| Generic
Manufacturers |
None
|
| Pharmacology
|
3-cyclopentylether
of ethinyl estradiol. Acts on receptors apparently the same
as endogenous estrogen. |
| Delivery
|
Oral
0.1mg tablets |
| Typical
dosage |
Pre-op
?
Post-op 0.1-0.2mg/wk |
| Availability
|
Approved
by U.S. FDA |
| Average
Wholesale Price |
$141.70/100
|
| Indications
|
Estrogen
replacement therapy in females |
| Contraindications
|
Active
blood clotting disorders. History of blood clotting disorder
in association with estrogen therapy. Known or suspected
breast cancer. Known or suspected estrogen-dependent tumors.
|
| Adverse
reactions |
- CNS
- Dizziness.
Headache. Mental depression. Migraine. Spasms of limb
and facial muscles.
- Eyes
- Intolerance
to contact lenses. Steepening of corneal curvature.
- Gastrointestinal
- Abdominal
cramps. Bloating. Cholestatic jaundice. Nausea. Vomiting.
- Skin
- Blood
eruptions from skin. Blotchy skin pigmentation. Increase
of body and facial hair. Loss of scalp hair. Red skin
patches from capillary congestion.
- Other
- Blood
clotting disorders. Breast and liver tumors. Elevated
blood pressure. Fluid retention. Gall bladder disease.
Increased calcium level in blood. Increased sensitivity
to light. Reduced carbohydrate and glucose tolerance.
|
| Comments
|
|